Risk for Incident VTE Increased in Adults With Atopic Dermatitis

Doug Brunk

June 07, 2023


Atopic dermatitis (AD) in adulthood appears to be associated with an increased risk for incident venous thromboembolism (VTE).


  • In a cohort analysis, researchers drew from Taiwan's National Health Insurance Research Database to identify 142,429 adults with AD newly diagnosed between 2003 and 2017 and 142,429 matched controls.

  • AD patients were subgrouped based on severity of their disease

  • Researchers used a Cox regression model to estimate hazard ratios (HRs) for VTE.

  • Stratified analyses according to age and sex were performed.


  • Adults with AD had an increased risk for incident VTE (HR, 1.28) compared with adults without AD, although the absolute difference in risk appeared to be small.

  • Individual outcome analyses revealed that AD was associated with elevated hazards for deep vein thrombosis (HR, 1.26) and pulmonary embolism (HR, 1.30).

  • In a sensitivity analysis that excluded systemic steroid users, the risk for VTE remained significantly increased among patients with AD (HR, 1.45).


This study is too preliminary to have practice application. Because of the study's limitations, "findings should be interpreted cautiously," the researchers write.


Tai-Li Chen, MD, of Taipei Veterans General Hospital, Taiwan, led the research, published May 31 in JAMA Dermatology.


The study used a claims database that lacked data on specific VTE risk factors, and ascertainment of AD and VTE was based on ICD codes.


Hualien Tzu Chi Hospital, Taiwan, funded the research. The researchers reported having no relevant financial relationships.  

For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.